Dubai (UAE) – The 33rd edition of the Société Internationale de Chirurgie Orthopédique et de Traumatologie (SICOT) has just concluded its proceedings in Dubai. This year’s meeting was combined with the 17th version of PAOA Orthopaedic World Conference.
SICOT is an international non-profit association that aims to promote the advancement of the science and art of orthopaedics and traumatology at international level in particular for the improvement of patient care, and to foster and develop teaching, research and education. It assembles delegates and exhibitors from around the world to discuss the latest developments in the orthopaedics. SICOT celebrated its 80th anniversary in 2009.
Genpharm and Tigenix participated in this year’s gathering to present the scientific research and clinical findings of ChondroCelect®, Tigenix’s innovative cell therapy, approved in Europe for patients suffering from degeneration of knee cartilage. ChondroCelect® is used in an autologous chondrocyte implantation procedure. Rene Verdonk, MD, Professor of Orthopaedic Surgery and Chief of Orthopaedic Surgery and Traumatology at the Ghent University Hospital, Belgium, presented the data to the delegates in various scientific sessions and discussed his experience and shared his insights with practicing orthopaedic surgeons in the MENA region.
About Genpharm Services
Genpharm Services is a pharmaceutical marketing company, based in the Dubai Biotechnology and Research Park, UAE. Through evidence-based medicine, Genpharm provides healthcare organizations with innovative therapeutic solutions in niche and rare genetic disease areas, market access strategies and sustainable commercial solutions in the Middle East and North Africa Region.
For more information, please visit www.genpharmservices.com
For more information
|Karim Smaira Chief Executive Officer email@example.com +971 4 422 70 10||Ashwathy Anil BusinessDevelopment Ashwathy@genpharmservices.com +971 4 422 70 10|